Dietmar Berger, Chief Medical Officer of Gilead Sciences, Inc. (NASDAQ:GILD), filed a Form 4 on September 11, 2026, disclosing transactions in common stock dated September 10, 2026, related to the vesting of restricted stock units.

Key Highlights

  • RSU vesting: 533 restricted stock units vested on September 10, 2026, each representing the contingent right to receive one share of Gilead Sciences common stock.
  • Shares withheld for taxes: 263 shares were disposed of at $144.81 per share on September 10, 2026, coded as an F transaction (payment of exercise price or tax liability).
  • Remaining direct ownership: Berger directly owns 19,522 shares of common stock following the reported transactions.
  • Remaining RSUs: 46,395 restricted stock units are beneficially owned directly following the reported transactions.
  • Vesting schedule: The restricted stock units carry a 4-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the balance vesting 6.25% quarterly thereafter until fully vested.
  • Filing signed by proxy: The form was signed by Amy Kim by Power of Attorney for Dietmar Berger on September 11, 2026.

Gilead Sciences CMO Dietmar Berger: RSU Vest and Tax Withholding Details

According to the filing, Dietmar Berger, who serves as Chief Medical Officer of Gilead Sciences, Inc., reported two transactions in Gilead common stock on September 10, 2026. The first was an M-coded transaction in which 533 restricted stock units converted into 533 shares of common stock, acquired at no stated price for the derivative exercise. The filing notes that each restricted stock unit represents the contingent right to receive one share of Gilead Sciences common stock.

The second transaction, coded F, reflected the disposal of 263 shares at a price of $144.81 per share. This type of transaction code is used to indicate the disposition of shares to satisfy a tax withholding obligation. Following these two transactions, the filing discloses that Berger directly holds 19,522 shares of Gilead common stock. In Table II, the filing also shows that Berger retains 46,395 restricted stock units beneficially owned directly after the reported activity.

The filing states that the restricted stock units vest over a 4-year schedule: 25% vest on the first anniversary of the grant date, with the remaining balance vesting at 6.25% per quarter until fully vested. The Form 4 was filed on September 11, 2026, and was signed by Amy Kim acting by Power of Attorney for Dietmar Berger.

What Was Disclosed

The filing reported the vesting of 533 restricted stock units and the withholding of 263 shares at $144.81 each by Gilead Sciences Chief Medical Officer Dietmar Berger on September 10, 2026, leaving him with direct ownership of 19,522 shares and 46,395 remaining RSUs.